Study found out the new treatment for HER2-positive breast cancer

It is reported that, according to the American Association for Cancer Research published in the journal "Clinical Cancer Research" on a laboratory study, when patients with HER2-positive breast cancer, trastuzumab (Herceptin) resistance, they may apply a replacement therapy.
     National Cancer Institute researcher, PharmD, ScD, Jacek Capala and his colleagues designed, manufactured and tested HER2-Affitoxin, which is a combination of HER-2 molecule and a specific affibody modified by bacterial toxins PE38 new protein.
     "HER2-targeted therapy with the current, such as Herceptin is different is that this protein does not interfere with signaling pathways of HER2, but HER2 as a target will pass a modified form of bacterial toxins, toxin specific for the HER2 positive tumor cells when the cells absorb this toxin, it will interfere with protein production, which can kill them, "Capala said.
     At least, these Capala laboratory occurred. In Affitoxin after injection into tumor-bearing mice, even relatively large, aggressive tumor will stop growing, most of which will disappear. This effect is strong enough, so that it is worth a Capala clinical.
     "Herceptin has revolutionized the treatment of patients with HER2-positive breast cancer, but a large number of tumors are resistant to the drug had," Capala said, "Affitoxin tumor in vivo can be for those who no longer respond to the Herceptin patients another treatment option. "

Posted in HER2-positive breast cancer